Covidien tube selected for programme

Covidien’s Hi-Lo Evac endotracheal tube has been named as part of Premier Healthcare Alliance’s Quest Comparative Innovation Programme (CIP).

The product is designed to ensure continuous aspiration of subglottic secretions to reduce ventilator-associated pneumonia.

It was selected on the basis of clinical evidence and potential impact on the Quest measurement areas of mortality, evidence-based care, cost of care, harm avoidance and patient experience.

Mike Alkire, president of Premier Purchasing Partners, said: “The Quest initiative stresses optimal performance in the areas of quality and cost of care, as well as patient satisfaction.”

“The Hi-Lo Evac tube aligns well with these goals, having been shown repeatedly to reduce the incidence of VAP.”

He went on to say the product also decreases the intensive care unit length of stay and duration of mechanical ventilation.

Last month, Covidien and Depomed announced an agreement which will see the former licensing rights to utilise the latter’s AcuForm gastric retentive drug delivery technology.

The deal will see the method used in the exclusive development of four undisclosed products, which – Covidien says – will target a key strategic focus in business, along with addressing medical needs.

Covidien employs 42,000 people in more than 130 countries around the world.